Chymotrypsin
Highest phase reached
Approved
Drug type
Protein
First approval year
1959
- First approval year
- 1959
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Chymotrypsin
- alpha chymar
- Alpha chymar
- catarase
- Catarase
- chymar
- Chymar
- chymoral
- Chymoral
- chymoral fte
- Chymoral fte
- deanase dc
- Deanase dc
- zolyse
- Zolyse
- zonulysin
- Zonulysin
- .alpha.-chymotrypsin
- .ALPHA.-CHYMOTRYPSIN [MI]
- alpha chymotrypsin
- alpha chymotrypsin mi
- chymotrypsin
- Chymotrypsin
- CHYMOTRYPSIN [EP IMPURITY]
- CHYMOTRYPSIN [EP MONOGRAPH]
- CHYMOTRYPSIN [GREEN BOOK]
- CHYMOTRYPSIN [HSDB]
- chymotrypsin [INN]
- CHYMOTRYPSIN [JAN]
- CHYMOTRYPSIN [ORANGE BOOK]
- CHYMOTRYPSIN [USP MONOGRAPH]
- CHYMOTRYPSIN [USP-RS]
- CHYMOTRYPSIN [VANDF]
- Chymotrypsin [WHO-DD]
- chymotrypsin ep impurity
- chymotrypsin ep monograph
- chymotrypsin green book
- chymotrypsin hsdb
- chymotrypsin inn
- chymotrypsin jan
- chymotrypsin orange book
- chymotrypsin usp monograph
And 7 more, listed on the interactive page.
- CAS registry numbers
- 9004-07-3
- ChEMBL ID
- CHEMBL1201465
- RxNorm IDs (RxCUI)
- 2530
- FDA ingredient codes (UNII)
- BVS505O332
- B06AA04
- S01KX01
Sources for recorded values
- First in class
- No
- Orphan designation
- No
- Availability
- discontinued
Administration routes
- topical
Mechanisms of action
- Mechanism
- Polypeptides proteolytic enzyme
- Action type
- PROTEOLYTIC_ENZYME
- Target
- Polypeptides
Investigated indications
- Condition
- Autistic Disorder
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003758
- Subject identifier
- D001321
- Condition identifier
- EFO_0003758
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005258
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005260
- Highest recorded phase
- 3
- NCT00881452
- NCT00912691
- NCT02410902
- NCT02649959
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (8)
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy
- Comparative Evaluation of Intraligamentary Injection of Dexamethasone, Diclofenac Sodium, and Chymotrypsin for Enhancing the Success of 4% Articaine Buccal Infiltration in Mandibular Molars With Symptomatic Irreversible Pulpitis
- Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain
- Comparison Of Acetaminophen, NSAIDs, And Trypsin-Chymotrypsin Plus Acetaminophen For Post-Endodontic Pain After Single-Visit Root Canal Treatment
- Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery
- Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.
- Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.
- Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns
Approved for (1)
In development for (2)
- Autism Phase 3
- Autism spectrum disorder Phase 3